Morgan Stanley’s Forte Biosciences FBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $956K | Sell |
45,007
-455,291
| -91% | -$10.8M | ﹤0.01% | 5222 |
|
|
2026
Q1 | $13M | Buy |
500,298
+429,767
| +609% | +$12.4M | ﹤0.01% | 3340 |
|
|
2025
Q4 | $1.92M | Buy |
70,531
+70,380
| +46,609% | +$1.23M | ﹤0.01% | 4839 |
|
|
2025
Q3 | $2.27K | Hold |
151
| – | – | ﹤0.01% | 7281 |
|
|
2025
Q2 | $1.95K | Hold |
151
| – | – | ﹤0.01% | 7227 |
|
|
2025
Q1 | $1.17K | Hold |
151
| – | – | ﹤0.01% | 7260 |
|
|
2024
Q4 | $3.43K | Hold |
151
| – | – | ﹤0.01% | 7099 |
|
|
2024
Q3 | $844 | Sell |
151
-1
| -0.7% | -$10 | ﹤0.01% | 7249 |
|
|
2024
Q2 | $2.04K | Buy |
152
+112
| +280% | +$1.81K | ﹤0.01% | 7063 |
|
|
2024
Q1 | $692 | Sell |
40
-40
| -50% | -$698 | ﹤0.01% | 7209 |
|
|
2023
Q4 | $1.63K | Buy |
80
+40
| +100% | +$559 | ﹤0.01% | 7158 |
|
|
2023
Q3 | $658 | Hold |
40
| – | – | ﹤0.01% | 7279 |
|
|
2023
Q2 | $1.03K | Sell |
40
-4
| -9% | -$104 | ﹤0.01% | 7289 |
|
|
2023
Q1 | $1.12K | Sell |
44
-13
| -23% | -$327 | ﹤0.01% | 7338 |
|
|
2022
Q4 | $1.42K | Buy |
57
+1
| +2% | +$26 | ﹤0.01% | 7420 |
|
|
2022
Q3 | $1K | Sell |
56
-13,426
| -100% | -$427K | ﹤0.01% | 7560 |
|
|
2022
Q2 | $438K | Sell |
13,482
-4,006
| -23% | -$127K | ﹤0.01% | 5483 |
|
|
2022
Q1 | $637K | Sell |
17,488
-26,966
| -61% | -$1.02M | ﹤0.01% | 5264 |
|
|
2021
Q4 | $2.38M | Buy |
44,454
+44,069
| +11,446% | +$2.96M | ﹤0.01% | 4437 |
|
|
2021
Q3 | $28K | Sell |
385
-1,016
| -73% | -$563K | ﹤0.01% | 6960 |
|
|
2021
Q2 | $1.18M | Buy |
1,401
+974
| +228% | +$878K | ﹤0.01% | 4986 |
|
|
2021
Q1 | $366K | Sell |
427
-201
| -32% | -$165K | ﹤0.01% | 5322 |
|
|
2020
Q4 | $572K | Buy |
628
+301
| +92% | +$283K | ﹤0.01% | 4996 |
|
|
2020
Q3 | $397K | Buy |
327
+278
| +567% | +$184K | ﹤0.01% | 4752 |
|
|
2020
Q2 | $18K | Sell |
49
-796
| -94% | -$356K | ﹤0.01% | 6031 |
|
|
2020
Q1 | $386K | Buy |
845
+683
| +422% | +$267K | ﹤0.01% | 4527 |
|
|
2019
Q4 | $32K | Buy |
162
+136
| +523% | +$30.8K | ﹤0.01% | 5978 |
|
|
2019
Q3 | $7K | Sell |
26
-59
| -69% | -$89.5K | ﹤0.01% | 6294 |
|
|
2019
Q2 | $214K | Sell |
85
-299
| -78% | -$887K | ﹤0.01% | 4995 |
|
|
2019
Q1 | $1.57M | Buy |
384
+270
| +237% | +$1.04M | ﹤0.01% | 3787 |
|
|
2018
Q4 | $350K | Sell |
114
-14
| -11% | -$60.3K | ﹤0.01% | 5019 |
|
|
2018
Q3 | $750K | Hold |
128
| – | – | ﹤0.01% | 4740 |
|
|
2018
Q2 | $447K | Sell |
128
-3
| -2% | -$11K | ﹤0.01% | 5175 |
|
|
2018
Q1 | $580K | Buy |
131
+10
| +8% | +$46.3K | ﹤0.01% | 4917 |
|
|
2017
Q4 | $466K | Buy |
121
+71
| +142% | +$283K | ﹤0.01% | 5014 |
|
|
2017
Q3 | $236K | Buy |
50
+4
| +9% | +$17.8K | ﹤0.01% | 5275 |
|
|
2017
Q2 | $210K | Buy |
+46
| New | +$259K | ﹤0.01% | 5303 |
|
Other funds holding FBRX
AAA
VCM
WP
IHAM
CS
Morgan Stanley's FBRX Position: Q2 2026 in Review
Morgan Stanley reduced its Forte Biosciences (FBRX) stake by 91% in Q2 2026, selling an estimated $10.8M and leaving 45,007 shares worth $956K. The position accounts for ﹤0.01% of the portfolio, ranked #5222.
Morgan Stanley first reported a position in FBRX in Q2 2017 and has held it in 37 quarters since. The position peaked at $13M in Q1 2026. 56 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.
- Morgan Stanley held 45,007 shares of Forte Biosciences worth $956K as of Q2 2026.
- Morgan Stanley sold 455,291 Forte Biosciences shares in Q2 2026, an estimated $10.8M.
- Forte Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5222 holding.
- Morgan Stanley first reported a position in Forte Biosciences in Q2 2017 and has held it in 37 quarters since.
- Morgan Stanley's Forte Biosciences position peaked at $13M in Q1 2026.
- 56 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.